Dynatronics (DYNTQ)
OTHER OTC:DYNTQ
Top Page
Dynatronics
(OTC:DYNTQ)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.01
▼(-75.00% Downside)
Action:ReiteratedDate:01/28/26
The score is driven primarily by weak financial performance (declining revenue, ongoing losses, high leverage, and strained cash flow). Technical indicators reinforce the risk with a pronounced downtrend and very weak momentum. Valuation does not offset these concerns because the negative P/E is not informative and there is no dividend yield support.
Positive Factors
Consumables / Repeat Revenue
A consumables business tied to installed equipment creates recurring revenue and predictable repurchase cycles. Over 2-6 months this supports revenue resilience and margin stability versus one-time device sales, improving cash predictability and customer stickiness for rehab clinics and distributors.
Negative Factors
Declining Revenue Trend
Sustained revenue decline reduces operating leverage and scale, pressuring margins and cash flow. Over 2-6 months this diminishes ability to invest in product development or sales, exacerbates margin compression, and makes recovery harder without structural demand or new channels.
Read all positive and negative factors
Positive Factors
Negative Factors
Consumables / Repeat Revenue
A consumables business tied to installed equipment creates recurring revenue and predictable repurchase cycles. Over 2-6 months this supports revenue resilience and margin stability versus one-time device sales, improving cash predictability and customer stickiness for rehab clinics and distributors.
Read all positive factors
Dynatronics (DYNTQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$24.07K
Dividend YieldN/A
Average Volume (3M)9.46K
Price to Earnings (P/E)―
Beta (1Y)-1.63
Revenue Growth-12.89%
EPS Growth-64.68%
CountryUS
Employees111
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,048,735
10 Day Avg. Volume9,367
30 Day Avg. Volume9,464
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.21
Price to Sales (P/S)0.02
P/FCF Ratio2.48
Enterprise Value/Market Cap257.10
Enterprise Value/Revenue0.23
Enterprise Value/Gross Profit1.07
Enterprise Value/Ebitda-0.66
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Dynatronics Business Overview & Revenue Model
Company Description
Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. Its orthopedic soft bracing products include c...
How the Company Makes Money
Dynatronics’ revenue has historically been generated primarily through the sale of physical medicine and rehabilitation products to healthcare providers and distributors. Key revenue streams have included (1) product sales of therapeutic modality ...
Dynatronics Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.81M | 27.39M | 32.53M | 40.61M | 44.34M | 47.80M |
| Gross Profit | 5.76M | 6.01M | 7.63M | 10.15M | 10.67M | 12.89M |
| EBITDA | -9.31M | -9.37M | -976.01K | -3.50M | -2.42M | 3.81M |
| Net Income | -10.74M | -10.90M | -2.70M | -5.66M | -4.73M | 1.21M |
Balance Sheet | ||||||
| Total Assets | 15.00M | 15.44M | 25.94M | 30.06M | 35.43M | 39.14M |
| Cash, Cash Equivalents and Short-Term Investments | 761.75K | 326.34K | 483.92K | 398.80K | 550.11K | 6.10M |
| Total Debt | 6.90M | 6.63M | 6.69M | 5.65M | 3.84M | 5.08M |
| Total Liabilities | 11.94M | 12.18M | 11.78M | 13.21M | 13.73M | 13.63M |
| Stockholders Equity | 3.06M | 3.26M | 14.16M | 16.86M | 21.70M | 25.51M |
Cash Flow | ||||||
| Free Cash Flow | 75.88K | 270.13K | -1.85M | 185.15K | -5.20M | 236.13K |
| Operating Cash Flow | 106.62K | 300.58K | -1.61M | 372.00K | -4.88M | 383.00K |
| Investing Cash Flow | -30.74K | -30.45K | -243.29K | -187.00K | -319.00K | 1.53M |
| Financing Cash Flow | 407.43K | -427.71K | 1.84M | -332.71K | -350.00K | 2.02M |
Dynatronics Technical Analysis
Negative
0.04
Price Trends
0.04
Negative
0.05
Negative
0.07
Negative
Market Momentum
>-0.01
Positive
27.37
Positive
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYNTQ, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.04, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 27.37 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DYNTQ.
Dynatronics Risk Analysis
Dynatronics disclosed 36 risk factors in its most recent earnings report. Dynatronics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dynatronics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $3.26M | -115.09 | -173.74% | ― | 82.96% | 82.04% | |
44 Neutral | $1.76M | -0.18 | -145.52% | ― | ― | 97.70% | |
42 Neutral | $20.93K | >-0.01 | ― | ― | ― | ― | |
41 Neutral | $2.50M | -0.69 | -6046.59% | ― | -8.93% | 97.80% | |
40 Underperform | $24.07K | -1.05 | -125.14% | ― | -12.89% | -64.68% |
* Healthcare Sector Average
DYNTQ
Dynatronics
0.01
-0.09
-89.00%
NUWE
Nuwellis
1.08
-38.32
-97.26%
VTAK
Catheter Precision
1.21
-4.68
-79.46%
BBLG
Bone Biologics
1.26
-2.86
-69.42%
BJDX
Bluejay Diagnostics
1.81
-8.51
-82.46%
DHAI
DIH Holdings US, Inc Class A
0.01
-3.39
-99.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.